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Introduction 
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 The human papillomavirus (HPV) is associated with several forms of cancer including 
anal, oral, penile and cervical (Gilbert, Brewer, Reiter, Ng, & Smith, 2010).  The initiation of 
Papinicoau (Pap) screening over 30 years ago to detect cervical dysplasia (often caused by HPV) 
resulted in early detection and treatment and a dramatic decline in deaths from cervical cancer 
(Palefsky, 2009).   
Nationally standardized cervical cancer screening exists for HPV related cervical cancer, 
however, universal screening protocols for HPV associated anal cancer is non-existent (Palefsky, 
2009).  In 1973, the rate of cervical cancer was 14.2 per 100,000, but with the advent of cervical 
Pap screening it has decreased to approximately 8 per 100,000 (Nanda, et al, 2000, Palefsky, 
1999).   
With the success of standardized cervical screening protocols, it is fair to suggest that 
similar screening protocols may be efficacious in the early detection of anal cancer.  A screening 
protocol for early detection and treatment of anal cancer, aimed at high-risk groups, such as men 
who have sex with men (MSM), could theoretically demonstrate reductions similar to cervical 
cancer, in deaths and morbidity from anal cancer.   
HPV and Anal Cancer 
Epidemiology 
 Statistically, anal cancer is rare; however, incidence varies by risk group.  In 2009, the 
American Cancer Society reported that there were 5290 new cases of anal cancer (3190 females 
and 2100 males).  Seven hundred and ten deaths (450 females and 260 men) were caused by anal 
cancer (The American Cancer Society, 2009).  Johnson, et al. (2004) found that among the 
general population diagnosis of anal cancer is 1.7 per 100,000 people, with women having a 
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slightly higher incidence.  Between 1998 through 2003, black men and women were diagnosed 
with anal cancer at a rate of 1.2 and 1.3, respectively (Centers for Disease Control [CDC], 2011).   
 Among HIV positive and negative men who have sex with men, statistics are drastically 
higher.  The incidence of anal cancer among men who have sex with men is estimated at 35 per 
100,000, statistics that are similar to the incidence of cervical cancer prior to the implementation 
of routine screening programs (Friedlander, et al., 2003; Arain, et al, 2005).  Prior to the HIV 
epidemic, the incidence of anal cancer was 35 cases per 100,000; after HIV and AIDS became 
prevalent the incidence of anal cancer soared to 70 cases per 100,000 in men who have sex with 
men (Palefsky, 1999; Oon & Winter, 2010).   
Individuals with compromised immune systems, as in HIV and AIDs, have a higher 
incidence of developing anal cancer.  The likelihood of developing anal cancer in men with a co-
morbid condition of HIV, increases thirty-five fold (Chaturvedi, 2010).  The mean age of 
diagnosis of anal carcinoma in HIV positive males is 40.9 years, compared with the general 
population at around age 60 (Frisch, Biggar, & Goedert, 2000).   
Pathophysiology, Histology, & Virology 
The natural progression of anal cancer isn’t clearly understood; however a correlation has 
been established between the human papillomavirus (HPV) and dysplastic effects, the precursor 
to anal cancer (Chaturvedi, 2010).  It is believed that the etiology of anal squamous cell 
carcinoma is equivalent to cancer of the cervix.  More than eighty genomes of HPV exist, and of 
those, nine types of genomes have been identified with anal dysplasia and cancer.  The high risk 
genotypes HPV 16 and HPV 18 are most prevalently linked to various types of cancer, including 
cervical, oral, and anal (zur Hausen, 1999; Abbas, Yang, & Fakih, 2010a, Palmer, et al, 1988).  
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Eighty-eight to 91% of anal cancers are caused by HPV 16 and 18 (Oon & Winter, 2010).  Of the 
2100 males diagnosed with anal cancer in 2009, 80% of those cases were associated with HPV 
oncogenes 16 and 18 (Kim, 2010).  Similar to cervical cancer, anal cancer typically develops in 
the transformation zone, where the change from columnar epithelium to squamous epithelium 
occurs (Palefsky, 1999).  The progression of HPV related anal dysplasia and cancer is 
accelerated when immunosuppression coexists with the human papillomavirus (Panther, Schlect, 
&Dezube, 2005).     
Risk Factors and Transmission 
 Multiple risk factors are associated with anal cancer, including HPV infection, receptive 
anal intercourse, number of lifetime partners, cigarette smoking, and history of genital warts 
(Abbas, et al, 2010a).  Daling, et al. (1987) found that history of anal receptive intercourse, 
genital warts, gonorrhea, and cigarette smoking were associated with an increased incidence of 
anal cancer.  Individuals with HIV who have lower CD4 counts, syphilis, anal warts, or hepatitis 
also pose a greater risk for developing anal cancer (Palefsky, 1999; Frisch, et al, 1997).  
Giuliano, et al, (2011) reports that the immune response to the human papillomavirus in men is 
lower than in women causing higher rates of HPV infection in the male population.    
Clinical Presentation  
  HPV related anal carcinoma presents with a wide array of symptoms.  The range of 
symptoms in anal carcinoma include being asymptomatic to weight loss, rectal bleeding, 
abdominal pain, change in bowel habits, and pain with anal receptive sex (Dyson & Draganov, 
2009; Panther, et al, 2005).  Nearly fifty percent of patients present with rectal bleeding, while 
thirty percent present with feelings of a mass or pain, and twenty percent are asymptomatic 
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(Abbas, et al, 2010a; Lindsey, et al, 2009).  Fifty percent of all anal cancer cases extend into the 
rectum or perineal skin, while in 10% of females, anal cancer proliferates into the anovaginal 
septum (Abbas, et al, 2010a)   
Literature Review 
 Several studies have examined the utility of using anal Pap screening as first line 
detection of anal dysplasia.  Examining the reliability of anal Pap screening is the first step in 
determining its utility in screening anal dysplasia.     
Diagnostic Tool 
 Table 1 provides a comparison of seven randomized controlled trial, examining the 
sensitivity and specificity of anal Papanicolaou screening.  Examination of the sensitivity and 
specificity of any tests provides the predictive value of correct positives and correct negative 
results that lends to the utility of the test.  Anal cytology provides screening with a high 
sensitivity ranging from 81-98%, assuring a high number of correct positive results.   
One may argue that the low rate of specificity or false negatives of anal pap testing is too 
low, averaging fifty percent of the seven randomized control trials.   However, literature reveals 
that anal Pap testing has a similar variable sensitivity and specificity to that of cervical Pap 
testing.  Nanda, et al (2000), found that in a review of twelve studies, the conventional Pap test 
for cervical screening had a sensitivity range from 30%-87% and a specificity from 86%-100%.  
Even though cervical dysplasia screening has a variable sensitivity and specificity, its use as a 
screening tool has significantly decreased mortality as a result of early detection and screening.  
Theoretically, anal dysplasia screening could demonstrate the same reductions in morbidity and 
mortality from anal cancer.  
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Table 1:  Summary of Studies Using Pap test as a Diagnostic Screening Tool for Anal Dysplasia  
Author/Title/Year N/Type of Study Findings 
Arain, et al.  The Anal Pap 
Smear:  Cytomorphology 
of squamous 
intraepithelial lesions, 
2005 
198 Males 
Retrospective Design 
High sensitivity (98%) for 
detection of ASIL, low 
specificity (50%) for 
predicting severity 
Cranston, et al.  The 
prevalence and predictive 
value of abnormal anal 
cytology to diagnose anal 
dysplasia in a population 
of HIV-positive men who 
have sex with men, 2007 
244 MSM and HIV + 
Cross Sectional Design 
Findings reported that anal 
cytology has positive 
predictive value with up to 
95.7% accuracy for any 
cytological abnormality 
and to predict high-grade 
dysplagia at 55.9% 
accuracy 
De Ruiter, et al.  A 
comparison between 
cytology and histology to 
detect anal intraepithelial 
neoplasia, 1994 
215 MSM 
Cross Sectional Design 
 
High sensitivity 88% with 
low specificity 16% 
Fox, et al.  The value of 
anal cytology and human 
papillomavirus typing in 
the detection of anal 
intraepithelial neoplasia:  a 
review of cases from an 
anoscopy clinic, 2005 
99 Males 
Cross Sectional Design 
Sensitivity 83%  
Specificity 38% 
Friedlander, et al.  
Anorectal cytology as a 
screening tool for anal 
squamous lesions, 2003 
51 
Cross Sectional Design 
 
Sensitivity 92% and 
specificity 50% 
Palefsky, et al.  Anal 
cytology as a screening 
tool for anal squamous 
intraepithelial lesions, 
1997 
658 MSM 
Cross Sectional Design 
 
 
A total of 2958 anal 
cytology samples were 
collected from 648 
subjects.  Initial cytology 
sensitivity was 69% in 
HIV + and 47% in HIV -.  
Subsequent anal cytology 
samples had a sensitivity 
of 81% and 50% 
respectively. 
Panther, et al. High 
resolution anoscopy 
findings for men who have 
sex with men:  Inacuracy 
of anal cytology as a 
predictor of histologic 
high-grade anal 
intraepithelial neoplasia 
and the impact of HIV 
serostatus, 2004 
153 
Cross Sectional Design 
Sensitivity 47%  
Specificity 90% 
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Continued Debate 
There has been debate over the utility of anal cytology Pap screenings; as a result of early 
studies that suggested its predictive value was not a useful determinant of abnormal anal 
cytology.  However, more recent studies indicate it may be a worthwhile screening tool.  This 
could be due to the switch from conventional slides to Thin Prep (Sherman, 1995).  In an 
examination of 117 conventional Pap smears and 191 Thin-Preps, satisfactory specimens were 
found to be 41% and 82.7% respectively (Sherman, 1995).  Friedlander, et al. (2003), found that 
when compared with conventional Pap smears, Thin-Preps detected eight times more squamous 
intraepithelial lesions.  While fecal matter, poor preservation, and air drying artifact tends to 
obscure conventional smears, Thin-Preps reduce these factors allowing for more satisfactory 
specimens for pathological evaluation (Friedlander, Stier, & Lin, 2003, Sherman, et al, 1995). 
A Consideration for Self-Collected Anal Cytology Samples 
 Fear of testing may lead some MSM to avoid screening in the clinic setting.  However, 
self-collected anal cytology samples provide a potential alternative to clinic testing.  Table 2 
provides a comparison of three randomized control trials examining the reliability of self-
collected anal cytology samples compared to clinic collected anal cytology samples.  Adequacy 
of specimens for pathologic review ranged from 80-91% of self-collected and 68-99% in 
clinician-collected anal cytology samples.  Sensitivity of the samples was provided in two out of 
the three randomized control trials and ranged from 60-68% for self-collected and 68-70% in 
clinician-collected anal cytology samples.  Empirical evidence supports that self-collected anal 
cytology samples may provide an alternative option for individuals who may not otherwise seek 
screening measures.  
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Table 2:  Summary of RCTs Comparing Self- and Clinician-Collected Anal Cytology Samples 
Author/Title/Year N Findings 
Chin-Hong, et al. 
Comparison of patient- 
and clinician-collected 
anal cytology samples to 
screen for human 
papillomavirus-associated 
anal intraepithelial 
neoplasia in men who 
have sex with men.  2008.   
125 MSM 
Cross Sectional Design 
 
 
Adequacy of specimens 
was 91% for clinician-
collected and 80% for 
self-collected specimens.  
Sensitivity of clinician-
collected specimens was 
68% and self-collected 
samples was 60%. 
Cranston, et al.  Self-
collected versus clinician-
collected anal cytology 
specimens to diagnose 
anal intraepithelial 
neoplasia in HIV-positive 
men.  2004. 
102 MSM 
Cross Sectional Design 
 
Adequacy of specimens  
for pathological review 
was 99% in clinician-
collected and 91% in self-
collected samples.  
Sensitivity of clinician-
collected samples was 
70% and self-collected 
was 68%. 
Lampinen, et al.  
Randomized clinical 
evaluation of self-
screening for anal cancer 
precursors in men who 
have sex with men.  2006. 
222 MSM 
Cross Sectional Design 
 
Adequacy of specimens 
for pathological review 
was 92% clinician-
collected and 83% self-
collected.  Information on 
sensitivity not provided.  
 
 It must be clearly understood that the utility of anal Pap screening would not be used to 
stage dysplasia, but to determine whether dysplasia is present or absent, similar to that of a 
cervical pap smear.  If dysplasia is determined, the necessity of high resolution anoscopy and 
biopsy would be required to stage the grade of dysplasia.   
Recommended Screening 
 Currently no national guidelines exist and routine screening is not recommended for the 
general population, however, recommendations for high risk populations do exist.  Initial 
screening is recommended for high risk individuals, including HIV-positive and HIV-negative 
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men who have sex with men, women who partake in anal receptive intercourse and individuals 
who are immunocompromised; the resultant anal cytology is the determinant for future follow 
up.   
A normal result requires a repeat screening every two years for HIV-negative MSM and 
annually for HIV-positive MSM (Panther, et al, 2005).  If the anal cytology is read as anything 
other than normal, the patient is referred for high resolution anoscopy (HRA), if no lesion if 
found then a repeat anal pap is performed in six months (Panther, et al, 2005).  If an anal 
intraepithelial neoplasia (AIN) grade 1 is found after the biopsy, a repeat pap and HRA after six 
months is recommended; if AIN  grade 2 or AIN grade 3 is found, the recommendation is to 
ablate the dysplastic cells and have a repeat pap and HRA in four to six months (Panther, et al, 
2005).  After anal cytology has been stable for two exams, screening can return to every twelve 
months (Panther, et al, 2005).    
Performing Anal Pap Screening 
 Performing anal Pap screening takes little to no preparation on the patient’s part, no 
bowel preparation is necessary, with the exception that the patient may need to evacuate their 
bowel prior to the procedure (Porche, 2006).  The patient is placed in the left lateral position, and 
a Dacron swab that is lubricated with tap water is inserted 1.5 to 2 inches into the rectum.  It is 
recommended that the swab be rotated 10-12 times while placing lateral pressure against the anal 
canal with the swab (Porche, 2006).  The swab is then placed in a liquid medium, such as 
ThinPrep, and labeled with the patient’s name, and other identifying information (Siekas & 
Aboulafia, 2009).   
Staging and Prognosis 
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 Five year survival rates for anal cancer are 80.1% for localized or cancer confined to a 
primary site, 59.8% for regional spread to lymph nodes, and 30.5% for anal cancer with 
metastatic spread (National Cancer Institute, 2010).  Prognosis and survival rates of anal cancer 
patients’ worsens with the co-morbitidity of HIV, one year mortality rates are 40% and five year 
mortality rates are 80% (Place, Gregorcyk, Huber, & Simmang, 2001).    
Cost Effectiveness 
 Two Markov models were developed to assess the cost-effectiveness of screening for 
anal dysplasia and anal cancer among HIV-positive and HIV-negative men who have sex with 
men.  The studies conducted found that screening HIV-positive MSM either annually or every 
two years and HIV-negative men every two to three years, will prolong quality adjusted life 
years while remaining cost effective (Goldie, et al, 1999; Goldie, et al, 2000).  Both studies 
found that the most influential factor was the progression of the lesions, regardless screening 
annually for HIV-positive MSM and every two to three years for HIV-negative MSM provided a 
accurate screening modality while decreasing the economic burden (Goldie, et al, 1999; Goldie, 
Kuntz, Weinstein, Friedberg, & Palefsky, 2000).   
Treatment  
A broad spectrum of treatments exists and treatment type is determined by the degree of 
cellular dysplasia.  High-grade anal intraepithelial lesions (the precursor to anal cancer) can be 
treated with trichloroacetic acid (either physician or patient applied), photodynamic surgery, 
electrocautery, or surgery (Abbas, et al., 2010b).  Post surgical complications, include, but are 
not limited to bleeding, perianal bleeding, and anal sphincter dysfunction (Chang, Berry, Jay, 
Palefsky, & Welton, 2002).  Recurrence rates twelve months post surgical was 79% for HIV-
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positive patients and zero recurrence for HIV-negative (Chang, et al, 2002).  Anal cancer 
treatment typically involves a combination of chemotherapy and radiation (Goldstone, 2005).  
Typical treatment for anal cancer begins with a week of chemotherapy, followed by five weeks 
of radiation, followed up with another week of chemotherapy (Abbas, 2010b, Goldstone, 2005).   
Billing 
 Careful coding is required to receive reimbursement for anal cytology screening.  Two 
different billing codes exist for anal cytology, one for using liquid-based cytology, such as 
ThinPrep, and the other for conventional slides (Darragh & Winkler, 2004). Coding anal 
cytology as a gynecological specimen will lead to reimbursement failure (Darragh & Winkler, 
2004).     
Barriers to Receiving Screening 
 Reed, Reiter, Smith, Palefsky, and Brewer (2010), found the biggest barriers to receiving 
anal Pap screening among MSM were modifiable beliefs and lack of education.  The most 
reported reasons for reluctance to testing was cost, lack of knowledge about the test, and 
embarrassment about getting the test (Reed, et al, 2010).  Understanding that modifiable beliefs 
and fears, whether real or perceived, place the provider in a unique position to educate and 
inform clients about a necessary screening tool that could potentially save lives.  
Education and Counseling 
 Several targeted interventions can be utilized in the prevention and screening of anal 
dysplasia.  First, community based and individual education needs to focus on risk factors, 
transmission, screening, and vaccination.  Community based education campaigns to educate the 
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public that anal dysplasia and cancer is a sexually transmitted infection, resultant from having 
unprotected anal receptive intercourse with an HPV positive partner.  Therefore, routine and 
correct condom use is recommended to prevent the spread of HPV.     
Second, if a patient is identified as high risk for HPV related anal cancer, education on 
the necessity, process, and frequency of screening is warranted.  Twenty-three percent of MSM 
have ever heard of an anal Pap and 14% had ever received an anal Pap (Reed, et al, 2010).  With 
these staggering statistics, it is important to stress the necessity of screening.  Fear of the 
procedure or anal cancer diagnosis can deter patients from asking about or being screened.  To 
ameliorate potential or real anxiety and fear, careful explanation and sensitivity to individual 
concerns is required.  Caring for the emotional and psychological aspect of the patient is crucial.   
Vaccination 
 In October 2009, the FDA approved licensure for the use of Gardisil in males ages nine 
to twenty-six for the prophylactic role of HPV induced genital condyloma (genital warts), 
potential risk factors for the development of anal cancer (CDC, 2010).  Yancey, et al (2010) data 
synthesis provides further supporting evidence that the quadrivalent vaccine Gardisil not only 
creates immunity from genital condyloma, it has the potential to decrease the incidence of HPV 
related anal dysplasia and cancer (Yancey, Pitlick, & Forinash, 2010).  One obstacle to getting 
boys and young men vaccinated is a knowledge gap among this population.  According to 
Gilbert, et al (2010), in a survey of 247 gay men only 21% thought that the HPV vaccine worked 
in men and 18% thought that the vaccination could be administered to males.   
 In 2011, results from a randomized, placebo-controlled, double-blind study was 
published regarding the use of the guadrivalent humanpapilloma vaccine to protect against HPV 
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16 and 18, the precursors to anal cancer (Giuliano, et al, 2011).  Giuliano, et al, (2011) found that 
receiving the three shot HPV regime significantly decreased the incidence of persistent infection 
caused by HPV 16, and 18 by 78.7% to 96.0%.  Although this study provides concrete evidence 
that the quadrivalent HPV vaccine decreases the incidence of persistent HPV infection, further 
research needs to be conducted to determine its effects on decreasing the incidence of anal 
cancer, as well as oral, vaginal, and vulvar cancers.  
Implications for Practice 
 Empirical data suggests that using anal cytology as a resource for surveillance programs 
is reliable and achievable; anal Papanicolaou screening should be considered a first line defense 
in early diagnoses.  Identification of anal dysplasia prior to it turning into invasive anal cancer is 
the goal of any successful screening program.  Primary care providers have a responsibility to 
serve at risk individuals and this begins with identifying individuals at a higher propensity for 
acquiring a disease or developing an illness.  Providers’ attitude and willingness to discuss 
sexual practices, prevention, screening options, and vaccinations is pivotal to the success of 
eliminating HPV related anal cancer in men who have sex with men.     
Collecting complete health histories and risk taking behavior analysis is essential in 
determining high risk individuals.  It is important as clinicians to remember to collect complete 
health history and a risk taking behavior analysis to determine at risk individuals.  It is not only 
important to screen at risk groups, but to also identify other high risk individuals, such as 
heterosexual men and women who partake in anal receptive intercourse, are immune suppressed, 
and who partake in high-risk sexual behavior.  Providers need to not shy away from asking 
individuals if they are not only sexually active, but if they participate in anal receptive 
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intercourse either currently or in the past.  Creating speaking points prior to a patient interview 
will assist in developing a comfort level when it comes to asking sometimes uncomfortable 
questions. 
 A critical question is how do we target prevention efforts towards high risk groups when 
no national guidelines exist?  Of utmost importance, is screening and treating anal dysplasia 
prior to it turning into anal cancer through improved prevention and surveillance campaigns.  
Clinicians need to be educated on the importance of an anal dysplasia screening program and 
trained on how to effectively collect samples.  Individuals providing anal cytology screening 
need to inform and educate clients about this option, become proficient at performing anal 
cytology, and explaining the procedure to clients.  Clinicians also need to be aware of follow up 
for someone presenting with abnormal anal cytology.   
Fear of discrimination can prevent patients from divulging the fact that they have 
partaken in high risk behavior/sexual encounters.  Due to fear of discrimination, it is important to 
provide a welcoming, prejudice-free, safe environment.  
Conclusion 
 HPV related anal dysplasia and cancer is a public health concern, just like other sexually 
transmitted infections.  Certain individuals and groups have a higher prevalence, including men 
who have sex with men, immune compromised individuals, and women with a history of cervical 
and/or vulvular dysplasia and cancer.  If this cancer is not caught early, it has disastrous effects.  
Due to the high rates in of anal dysplasia and cancer in MSM, it is logical to implement a 
screening program, similar to the cervical pap screening program.  It is fair to estimate that the 
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implementation of a universal surveillance program could provide the same epidemiological 
results for anal cancer in men who have sex with men.     
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Recommended Internet Sites 
 The internet sites listed below can serve as resources for information regarding anal 
dysplasia and cancer, and disease statistics.  The gay and lesbian medical association website 
provides a database of medical providers and practitioners that support and provide a safe health 
care environment for gay, lesbian, and transsexual individuals. 
The American Cancer Society  http://cancer.org 
The National Cancer Institute  http://www.cancer.gov 
The Center for Disease Control http://www.cdc.gov 
American Social Health Association http://www.ashastd.org 
World Health Organization http://www.who.int 
Gay and Lesbian Medical Association  http://www.glma.org 
The Rainbow Health Initiative www.rainbowhealth.org 
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